Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for ResMed (RMD) This Earnings Season?

Corteva Inc

Ford Motor Company

Halliburton

Southwest Airlines

Norwegian Cruise Line

Nielsen Hlds

NRG Energy

Pfizer

Twitter

The three major U.S. equities indexes closed lower again on Friday for the fourth day in a row.

5 S&P Winners, 5 Losers in Monday's Premarket

The heavy selling pressure might have exhausted for ResMed (RMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Down 9.2% in 4 Weeks, Here's Why You Should You Buy the Dip in ResMed (RMD)

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2022 on Thursday, January 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

ResMed to Report Second Quarter Fiscal 2022 Earnings on January 27, 2022

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, beginning at approximately 1:30 p.m. (Eastern Standard Time) via webcast.

ResMed Announces Participation in the 40th Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 30, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6, 2022, beginning at approximately 4:00 p.m. (Eastern Standard Time).

ResMed Announces Participation in the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference

Abbott Labs

ABT vs. RMD: Which Stock Is the Better Value Option?

ABT or RMD: Which Is the Better Value Stock Right Now?

This is an evaluation of likely coming stock prices, not an appraisal of RMD's product line or management's competitive abilities. They're already evaluated by big-$ investment analysts and portfolio managers. The buys they urge as volume “block trades” cause Market-Makers to put firm capital temporarily at risk, balancing shares supply with demand. And to hedge-protect the risks created.

ResMed Inc.: Another Example Of Best Medical Devices Near-Term Buy - As Seen By Market-Makers

SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has elected Desney Tan and John Hernandez, both digital health leaders at world-leading tech companies, to its board of directors, during its annual stockholders' meeting.

ResMed Elects Health Tech Leaders Desney Tan and John Hernandez to Its Board of Directors

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Credit Suisse 30th Annual Healthcare Conference on Wednesday, November 10, 2021, beginning at approximately 1:00 p.m. (Eastern Standard Time) via video webcast.

ResMed Announces Participation in the Credit Suisse 30th Annual Healthcare Conference

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

ResMed Inc. (RMD) CEO Mick Farrell on Q1 2022 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 11.85% and 5.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2022

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

AbbVie

Walgreens

Three healthcare stocks that have momentum on their side and are good buys right now.

3 Leading Healthcare Stocks to Buy in 2021 and Beyond

Fulgent Genetics

Johnson & Johnson

Each has its own reason for being in your portfolio.

3 Top Healthcare Stocks to Buy Right Now

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2022 on Thursday, October 28, 2021, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

ResMed to Report First Quarter Fiscal 2022 Earnings on October 28, 2021

ResMed Inc.: Best Price-Positioned Medical Supply Industry Stock, As Seen By Market-Makers

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

Continued PAP use linked to 39% higher chance of survival over a 3-year period Continued PAP use linked to 39% higher chance of survival over a 3-year period

People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS

David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Pendarvis sold 1,487 shares of Resmed at a price of $292.16 per share.

Chief Administrative Officer Of Resmed Makes $434.44 Thousand Sell

James Hollingshead , President of  Resmed (NYSE: RMD ), made a large insider sell on September 1, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Wednesday showed that Hollingshead sold 2,400 shares of Resmed at a price of $287.3 per share.

President Of Resmed Makes $689.53 Thousand Sell

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021, beginning at approximately 1:15 p.m. (Eastern Daylight Time) via video webcast.

ResMed Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business Change intended to drive rapid digital transformation, leverage full scale of cloud-connected technology platforms, and accelerate growth of ResMed's SaaS business

News for ResMed Stock (RMD)